Diabetes mellitus is the leading cause of end-stage renal disease. Development and progression of diabetic nephropathy result from a combination of genetic susceptibility and metabolic and hemodynamic abnormalities. In America, some racial and ethnic minorities have a significant burden of diabetic nephropathy, and, although genetic studies suggest that inherited factors play a major role in the pathogenesis of diabetic nephropathy, little information has been gained on the genes and molecular mechanisms involved. The genetic background of diabetic nephropathy is believed to be polygenic, and the genes predisposing to the development and progression of diabetic nephropathy are actively being investigated. New knowledge in identifying and understanding the role of susceptibility gene(s) will provide valuable information that could help develop new preventive and therapeutic strategies.
INTRODUCTION
Diabetic nephropathy (DN) is a common and serious microvascular complication of both type 1 and 2 diabetes mellitus (DM). DN is associated with end-stage renal disease (ESRD) and premature death from cardiovascular disease. 1 Signs of DN may be detected as early as 5 years after the onset of hyperglycemia. The main criteria used for definition of nephropathy include the presence of changes in glomerular filtration rate, microalbuminuria or clinical proteinuria, and hypertension, as well as characteristic histologic lesions. Microalbuminuria, defined as a urinary albumin excretion rate of 30-299 mg/d, 2 is a marker for DN and cardiovascular disease and precedes overt or clinical proteinuria ($500 mg protein/24 h or $300 mg albumin/24 h) by several years. Microalbuminuria is the most reliable predictor of DN in type 1 diabetes, but microalbuminuria may precede the development of DN in type 2 DM. The risk of progression from microalbuminuria to proteinuria is reported to be 20%-53% over 5-10 years. 3 It is believed that hyperglycemia damages the kidney through the accumulation of advanced glycation end products, the activation of selected protein kinase C isoforms, and the activation of aldose reductase pathways. 4 However, recent findings of development of DN in some patients in spite of good metabolic control, although not in other patients, even after years of uncontrolled hyperglycemia, together with evidence of familial aggregation and racial differences in the incidence of DN, suggest that genetic factors are important in its pathogenesis. It is now widely accepted that the development and progression of DN result from a combination of genetic predisposition as well as metabolic and hemodynamic abnormalities.
In this article, we review the evidence for a role of genetic factors that may contribute to the development and progression of DN.
The familial aggregation of DN has been found in diverse populations with both type 1 and 2 DM. Although a high proportion of patients with ESRD secondary to DN have type 2 DM, genetic research has mainly concentrated on patients with type 1 diabetes. Reports from Sweden and America have shown that diabetic siblings of individuals with type 1 DM and DN have a 4.8-fold increased risk of developing DN, compared with diabetic siblings of individuals without DN. 5 In this study, DN was observed in 83% of diabetic siblings of diabetic probands with nephropathy and in 17% of siblings of probands without nephropathy. Furthermore, 41% of the siblings of probands with nephropathy had ESRD. Another study of 110 probands, examined for nephropathy status found that the cumulative incidence of nephropathy for siblings of probands with DN was 71.5% and only 25.4% for siblings of probands without nephropathy. 6 The magnitude of the risk difference between the 2 groups of siblings suggests that genetic influences are major determinants of DN.
Familial clustering of DN in type 2 DM was also supported by many family studies in diverse populations, including Mexican Americans. Approximately 5%-10% of white patients with type 2 diabetes develop ESRD. 7 However, the incidence of ESRD varies considerably among different ethnic groups and is higher among minority populations including Mexican Americans. 8, 9 Mexican Americans are among the largest minority groups in the United States. The prevalence of type 2 DM in Mexican Americans is 2 to 3 times higher than in whites. 10, 11 Population-based studies of Mexican Americans with type 2 DM have shown that these patients are 3 times more likely to develop microalbuminuria and 4 times more likely to develop clinical proteinuria compared with non-Hispanic white diabetic subjects. 12, 13 Even, the nondiabetic siblings of probands with type 2 diabetes have higher albumin excretion rates than siblings of subjects without diabetes. 14, 15 This suggests that predisposition to nephropathy may be manifested as elevated urine albumin excretion in normoglycemic subjects, whereas this phenotype progresses to overt proteinuria and ESRD in the presence of diabetes. Evidence of familial aggregation of type 2 DM-related renal disease was also supported from other population studies in Italy, 16 Brazil, 17 and India. 18 Not only the incidence of DN but also the rate of progression varies with ethnicity. Although not many data are available with regards to progression of DN in Mexican Americans, it has been shown that Mexican Americans with type 2 DM have 6 times higher chance of developing ESRD compared with whites. 19 This may be influenced by genetic factors independent of those controlling hypertension, diabetes, hyperlipidemia, and response to angiotensin-converting enzyme inhibitors, all of which are known to alter the course of disease progression.
Microalbuminuria is a risk factor for premature cardiovascular morbidity and mortality. Several reports reveal the tight clustering of albuminuria in the diabetic and nondiabetic members of multiplex families with type 2 DM. [20] [21] [22] Proteinuria and elevated serum creatinine concentrations were studied in Pima Indian families with type 2 DM in 2 generations. 23 Proteinuria occurred among 14% of the diabetic offspring of diabetic parents if neither parent had proteinuria, 23% if one parent had proteinuria, and 46% if both parents had diabetes with proteinuria. The familial aggregation of an elevated creatinine was limited to male offspring, among whom 11.7% had elevated creatinine if the parent had elevated creatinine but only 1.5% did so if the diabetic parent had normal creatinine. These data demonstrate that proteinuria and elevated creatinine aggregate in Pima families and suggest that the susceptibility to renal disease is inherited independently of the diabetes status.
Furthermore, in Pima Indians, urine albumin excretion measured as albumin-to-creatinine ratio showed a moderate evidence of linkage on chromosome 7q (D7S1804) and less evidence of linkage on chromosome 20 (D20S473) and chromosome 3 (D3S1763). 24 The region on chromosome 7 contains 3 potential candidate genes: the aldose reductase (ALDR1), endothelial nitric oxide synthase-3 (NOS3), and the T-cell receptor bchain (TRCBC). However, none of these gene polymorphisms explained the linkage. Recently, a genome-wide scan for ACR revealed a LOD score of 2.7 on chromosome 19 near the marker D19S591 in hypertensive patients. 25 It is evidently clear that DN clusters in families and has a strong genetic basis.
CANDIDATE GENE ANALYSIS FOR DN
A number of genetic loci have been analyzed in detail for association with DN. The genes encoding components of the renin-angiotensin system received greatest attention due to the central role played by this system in the regulation of blood pressure, Na + metabolism, and renal hemodynamics. A linkage analysis conducted on a candidate region for albuminuria in type 1 diabetes found evidence of linkage near the marker angiotensin II type 1 (AT1) receptor on chromosome 3q. 26 However, the DNA variants identified in this locus do not contribute to the linkage. An association between the 256-bp insertion/deletion (I/D) polymorphism in intron 16 of the gene encoding the angiotensin I-converting enzyme (ACE) and DN in type 1 diabetic patients has been extensively studied by several groups. 27 Although this polymorphism does not appear to be a strong candidate for DN development, it appears to play a major role in influencing the response to angiotensin-converting enzyme inhibitors on the progression of DN. 26, 28 Type 2 diabetic patients with the DD genotype have a higher incidence of progressive renal disease and a faster progression to ESRD. 29 Although the I/D polymorphism plays a major role in disease progression of DN in patients of Japanese origin with type 2 DM, it did not contribute to the development of the disease in Chinese patients with type 2 DM. 30 The angiotensinogen (AGT) gene also received considerable attention for its role in the pathogenesis of DN. Polymorphism of the T allele of M235T of AGT was shown to be associated with cardiovascular disease. 31 However, except for hypertension, this was not replicated for coronary artery disease with larger study population groups. 32 Genetic loci shown to have positive association with nephropathy/albuminuria include apolipoprotein E (ApoE), heparan sulfate (HSPG), aldose reductase (ALR2), human leucoycte antigen (HLA), insulin (INS), angiotensinogen (AGT), angiotensin II type 1 receptor (AGTRI), atrial natriuretic peptide (ANP), N-acetyl transferase 2, protein kinase C-1 (PRKCB1), Podocin (NPHS2), and RANTES. Genes examined in type 1 or 2 DM where no association has been found include platelet glycoprotein 3a, bradykinin receptor, paraoxonase 1 (PONI), methylenetetrahydrofolate reductase (MTHFR), G-protein beta-3 subunit and Nephrin. However, it should be noted that some of the association studies have not been consistent in every population.
Potential genetic linkage between 8 cytokine genes and DN was studied. Several polymorphisms were identified in epidermal growth factor (EGF); plateletderived growth factor-b (PGDF)b; transforming growth factor (TGF)b 1, 2, and 3; tumor necrosis factor (TNF)a and b; and interleukin-1 receptor antagonist gene. However, none of these loci played a major role in initiation of renal failure in African Americans with ESRD secondary to hypertension, diabetes, or chronic glomerulonephritis. 33 Another study examined linkage between ESRD and the renal failure susceptibility gene Rf-1 and found no evidence of linkage between ESRD and markers on 10q where the human homologue of Rf-1 is located. 34 Endothelial dysfunction is closely associated with the development of diabetic retinopathy, DN, and atherosclerosis in both type 1 and 2 DM. Recent findings indicate that DNA variations in the endothelial NO synthase gene (eNOS) could contribute to the endothelial dysfunction and indirectly to the development of DN. 35 Insulin resistance has been related to the presence of DN especially in type 1 microalbuminuric patients 36 and underlies many of the alterations of DN, including high BP, lipid abnormalities, increased left ventricular mass, and a family history of hypertension and cardiovascular disease. 37 It is presumed that albuminuria, cardiovascular disease, and hypertension are linked and may predispose to insulin resistance. 38 Recently, a role of specific inhibitors of insulin signaling has been described in humans with diabetes and insulin resistance. Membrane glycoprotein PC-1 (plasma cell differentiation antigen-1), also known as ectonucleotide pyrophosphatase/phosphodiesterase (ENPP1), is expressed in many tissues and inhibits insulin signaling either at the level of the insulin receptor or downstream at a postreceptor site. 39 Elevated PC-1 levels in insulin target tissues may play an important role in the development of insulin resistance in obesity and type 2 DM. An amino acid polymorphic variant of PC-1, K121Q (lysine to glutamine) was reported to be associated with insulin resistance. 40 PC-1 121Q allele might predispose to early myocardial infarction independent of other well-established risk factors. Because insulin resistance is present in diabetic patients with albuminuria, the impact of K121Q on DN was extensively studied in both type 1 and 2 DM. De Cosmo et al 41 reported an association of K121Q with low GFR in type 1 patients with DN. In addition, K121Q could interact with ACE I/D polymorphism in an additive fashion to predict the rate of decline of GFR. 42 Conversely, Jacobsen et al 43 did not find any impact of this polymorphism in a similar population of Danish patients with type 1 DM. In a stratified analysis according to duration of diabetes, the risk of early-onset ESRD for carriers of the Q variant was 2.3 times that for noncarriers. 44 Albuminuria is heritable in Mexican-American families participating in the San Antonio Family Diabetes Gallbladder Study (SAFDGS). We performed a genome-wide scan to identify chromosomal regions harboring loci that influence susceptibility to albuminuria in Mexican Americans participating in SAFDGS. Preliminary multipoint linkage analysis indicated strong evidence of linkage to a genetic location near marker GABRB3 on chromosome 15q12 (LOD score 3.1, P = 0.000855). This region also exhibited a LOD score of 2.5 with diabetes and 3.0 with hypertension as covariates, suggesting that the effect of this locus on albuminuria is also largely independent of diabetes and hypertension. The results of a repeat analysis with a larger number of patients are expected to be ready in 2006 (personal communication).
To date, a number of approaches including animal models, genetic association studies, affected sib pair, discordant sib pair, and transmission distortion analysis has been used to dissect this polygenic disease. The majority of the genetic studies have analyzed concordant affected sib pairs or performed association studies based on unrelated individuals. However, the existing data for most of these DN genes and genetic loci are not conclusive, and some of these associations have not been reproduced in larger studies. The consistency of the findings of familial aggregation of DN and of its coaggregation with other subphenotypes makes a genetic component likely. The ultimate proof lies in identifying the genes responsible for DN, which would increase the knowledge about the risk for a given patient and help in facilitating new therapeutic approaches. Table 1 shows a summary of some selected candidate gene variants associated with DN.
The National Institutes of Health created a multicenter consortium entitled Family Investigation of Nephropathy and Diabetes (FIND), with the goal of localizing and identifying genetic factors that modulate susceptibility to DN in European Americans, African Americans, Mexican Americans, and Native Americans throughout the United States, using genome-wide linkage analyses and mapping by admixture linkage disequilibrium techniques. 46 Eight participating centers will enroll nearly 10,000 individuals by September 2004, and data analysis is expected to be ready in 2006. It is hoped that this initiative will shed valuable information about the genetics of DN that could help predict which individuals are at increased risk of disease development and progression.
